Myelodysplastic syndrome (MDS) is a group of bone marrow disorders where the body fails to produce enough healthy blood cells, leading to symptoms like fatigue, infections, and bleeding. While there is currently no universal cure, treatment strategies aim to slow disease progression, reduce symptoms, and improve quality of life—ranging from supportive care and medications to advanced stem cell transplantation and innovative therapies being tested in clinical trials.

How Treatment Works to Control Myelodysplastic Syndrome

When someone receives a diagnosis of myelodysplastic syndrome, often called MDS or myelodysplasia, they face a disease that affects the bone marrow’s ability to create functional blood cells. The bone marrow, which normally acts like a factory producing red blood cells, white blood cells, and platelets, starts making abnormal or immature cells that don’t work properly. This failure leads to low blood counts, known as cytopenias, which cause many of the challenging symptoms people with MDS experience.^[1]

Treatment for MDS is not one-size-fits-all. The approach depends heavily on the specific type of MDS, how severe the blood count problems are, the patient’s age and overall health, and whether the disease is considered low-risk or high-risk. For some people, particularly those with lower-risk MDS and few symptoms, treatment may not be needed right away. Instead, doctors recommend regular monitoring with blood tests to watch for any changes. This approach is sometimes called “watch and wait” or active monitoring, and it helps avoid unnecessary treatment side effects when the disease is stable.^[2]

The primary goals of MDS treatment are to slow down disease progression, manage symptoms, prevent complications like severe anemia or infections, and maintain the best possible quality of life. In some situations, especially for younger patients with higher-risk MDS who are otherwise healthy, treatment may aim for a potential cure through stem cell transplantation. For many others, treatment focuses on controlling the disease and helping them feel better day to day.^[7]

Understanding which type of MDS someone has is crucial because it influences treatment decisions. Healthcare providers use classification systems to categorize MDS based on how the blood and bone marrow cells look under a microscope, the percentage of immature cells called blasts, and specific genetic or chromosomal changes. Some types of MDS progress slowly and rarely transform into acute leukemia, while others carry a higher risk of developing into acute myeloid leukemia, or AML, which happens in about 30% of MDS cases overall.^[3]

Standard Treatment Options for Myelodysplastic Syndrome

Standard treatment for MDS includes several established approaches that have been used for years and are recommended by medical guidelines. The choice among these depends on whether someone has low-risk or high-risk disease, their symptoms, and their overall fitness for different types of therapy.

Supportive Care and Blood Transfusions

For many people with MDS, supportive care forms the backbone of treatment. This approach doesn’t target the MDS itself but helps manage the problems it causes. Blood transfusions are one of the most common supportive treatments. When red blood cell counts drop too low and cause severe anemia, patients may receive transfusions of red blood cells to restore their energy and reduce shortness of breath. Similarly, if platelet counts fall dangerously low and bleeding becomes a concern, platelet transfusions can help prevent or stop bleeding.^[7]

Regular blood transfusions can significantly improve quality of life, but they come with their own challenges. Over time, repeated transfusions can lead to a buildup of iron in the body, called iron overload. This excess iron can damage organs like the heart and liver. To prevent this, doctors may prescribe iron chelation therapy—medications that help remove excess iron from the body. These medications include deferasirox, which is taken by mouth, and deferoxamine, which is given by injection or continuous infusion under the skin.^[7]

Growth Factors to Stimulate Blood Cell Production

Another standard treatment involves medications called growth factors or hematopoietic growth factors. These are proteins that stimulate the bone marrow to produce more blood cells. Erythropoiesis-stimulating agents, such as epoetin alfa and darbepoetin alfa, encourage the production of red blood cells. They work similarly to a natural hormone called erythropoietin that the kidneys produce to signal the bone marrow to make red blood cells.^[9]

These medications are given as injections under the skin, usually once a week or every few weeks, depending on the specific drug and the patient’s response. They can help reduce the need for red blood cell transfusions in some patients, particularly those with lower-risk MDS who have relatively low levels of natural erythropoietin in their blood. However, they don’t work for everyone, and their effectiveness varies from person to person.^[9]

There are also growth factors for white blood cells, such as granulocyte colony-stimulating factor (G-CSF), which can help increase the number of infection-fighting white blood cells. These may be used when patients develop severe infections or have very low white blood cell counts that put them at high risk.^[13]

Hypomethylating Agents

For patients with higher-risk MDS, or those whose disease has not responded to other treatments, hypomethylating agents are a key standard therapy. These medications, which include azacitidine and decitabine, work by affecting how genes are expressed in cells. They remove chemical tags called methyl groups from DNA, which can help restore normal function to genes that control cell growth and development.^[12]

Azacitidine is typically given as an injection under the skin for seven days in a row, followed by a rest period, in cycles that repeat every 28 days. Decitabine is given intravenously, usually over shorter cycles. A newer formulation combines decitabine with cedazuridine in a pill that can be taken by mouth, making treatment more convenient for patients.^[9]

These medications don’t cure MDS, but they can slow disease progression, reduce the need for transfusions, improve blood counts, and potentially delay transformation to acute leukemia. Treatment typically continues for several months to see if it’s working, and if beneficial, it may be continued long-term. Common side effects include low blood counts (which may initially worsen before improving), fatigue, nausea, injection site reactions, and increased risk of infection.^[12]

Immunomodulatory Drugs

For certain types of MDS, particularly MDS associated with a specific chromosomal abnormality called deletion 5q (or del(5q)), the drug lenalidomide is a highly effective treatment. Lenalidomide is an immunomodulatory drug, meaning it works by modifying the immune system and also has direct effects on cancer cells.^[13]

In patients with del(5q) MDS who are transfusion-dependent, lenalidomide can significantly reduce or eliminate the need for red blood cell transfusions. It’s taken as a daily pill, usually for three weeks followed by one week off, in repeating cycles. The medication can cause side effects including low blood counts, particularly a drop in platelets and white blood cells, as well as fatigue, diarrhea, skin rash, and itching. Blood counts need to be monitored closely, and doses may need to be adjusted based on how the body responds.^[13]

Immunosuppressive Therapy

Some patients with MDS, particularly those with hypoplastic (underactive) bone marrow, may benefit from immunosuppressive therapy. This approach uses medications like antithymocyte globulin (ATG) and cyclosporine to suppress the immune system. The rationale is that in some cases, the immune system may be inappropriately attacking the bone marrow, contributing to the failure to produce healthy blood cells.^[11]

This treatment is more commonly used in younger patients with specific MDS characteristics and is given in a hospital setting over several days. While not effective for everyone, some patients experience significant improvement in their blood counts with this approach.^[13]

Stem Cell Transplantation

The only treatment that can potentially cure MDS is allogeneic hematopoietic stem cell transplantation, also called a bone marrow transplant. In this procedure, the patient receives high doses of chemotherapy, sometimes combined with radiation, to destroy their diseased bone marrow. They then receive healthy stem cells from a matched donor, which can rebuild a new, healthy blood-forming system.^[7]

However, stem cell transplantation is a demanding treatment with significant risks, including infections, graft-versus-host disease (where the donor cells attack the patient’s body), and transplant-related complications that can be life-threatening. It’s generally reserved for younger patients (typically under 65 or 70) who are otherwise healthy, and for those with higher-risk MDS where the potential benefit outweighs the risks. The decision to proceed with transplant involves careful evaluation of the patient’s overall health, the aggressiveness of their MDS, and the availability of a suitable donor.^[9]

For older patients or those with significant health problems, reduced-intensity transplants may be an option. These use lower doses of chemotherapy before the transplant, which can be safer but may also be less effective at eliminating the MDS.^[11]

Promising Treatments Being Studied in Clinical Trials

While standard treatments help many patients with MDS, researchers continue to search for more effective therapies with fewer side effects. Clinical trials are testing new drugs and approaches that may become standard treatments in the future.

Novel Erythroid Maturation Agents

One of the most promising recent developments in MDS treatment is luspatercept, an erythroid maturation agent. Unlike erythropoiesis-stimulating agents that try to produce more red blood cells, luspatercept works differently—it helps immature red blood cells develop into mature, functional ones. It does this by blocking certain proteins that interfere with red blood cell maturation.^[9]

Luspatercept has been approved for use in patients with certain types of MDS, particularly those with ring sideroblasts (a specific abnormality seen in red blood cells) who require regular transfusions. Clinical trials have shown that it can reduce or eliminate the need for transfusions in a significant percentage of patients. It’s given as an injection under the skin every three weeks. Common side effects include fatigue, muscle and bone pain, dizziness, and headache.^[9]

Targeted Therapies for Specific Genetic Mutations

As scientists better understand the genetic changes that drive MDS, they’re developing targeted therapies aimed at specific mutations. Clinical trials are exploring drugs that target mutations in genes like TP53, IDH1, IDH2, and FLT3, among others. These mutations are found in subsets of MDS patients and can influence how the disease behaves.^[5]

For example, IDH inhibitors are being studied for MDS patients whose cells carry mutations in the IDH1 or IDH2 genes. These medications work by blocking the abnormal enzyme produced by the mutated gene, which can help restore normal blood cell development. Similar drugs are already approved for acute myeloid leukemia, and studies are testing whether they can help MDS patients as well.^[11]

Another area of research involves drugs that target splicing factor mutations. Many MDS patients have mutations in genes that control how genetic information is processed in cells (a process called RNA splicing). Experimental drugs that correct or work around these splicing errors are in early-phase clinical trials.^[5]

Combination Therapies

Researchers are also testing whether combining different types of treatments can be more effective than using them alone. For example, clinical trials are examining combinations of hypomethylating agents with targeted therapies, immunomodulatory drugs, or other chemotherapy agents. The goal is to attack the MDS cells through multiple mechanisms simultaneously, potentially leading to better responses and longer-lasting benefits.^[11]

Some studies are combining drugs like azacitidine or decitabine with lenalidomide, checkpoint inhibitors (a type of immunotherapy), or venetoclax (a drug that helps cancer cells die). Early results from some of these combination studies have shown promise, with improved response rates compared to single-agent therapy in some patient groups.^[11]

Immunotherapy Approaches

Immunotherapy—using the body’s immune system to fight disease—is being explored in MDS. One approach involves checkpoint inhibitors, drugs that help the immune system recognize and attack cancer cells by blocking proteins that normally prevent immune responses. These medications have shown remarkable success in other cancers, and studies are testing whether they can help MDS patients, either alone or in combination with other treatments.^[11]

Another immunotherapy strategy being studied involves antibodies that target specific proteins on MDS cells. By attaching to these proteins, the antibodies can mark the cancer cells for destruction by the immune system or deliver toxic substances directly to them.^[11]

Clinical Trial Phases and What They Mean

Clinical trials testing new MDS treatments typically progress through several phases. Phase I trials are the first tests in humans and focus primarily on safety—determining the right dose and identifying side effects. These trials usually involve small numbers of patients. Phase II trials test whether the treatment works against MDS, measuring how many patients respond and how well the treatment controls the disease. These involve more patients than Phase I. Phase III trials compare the new treatment directly against standard treatment in large numbers of patients to definitively determine if it’s better, safer, or more convenient.^[11]

Patients interested in clinical trials can discuss options with their doctors. Trials may be available at major cancer centers in the United States, Europe, and other regions. Eligibility depends on factors like the type and risk level of MDS, previous treatments received, overall health status, and specific requirements of each trial.^[7]

Most common treatment methods

• Supportive care
  • Red blood cell transfusions to treat anemia and restore energy
  • Platelet transfusions to prevent or stop bleeding
  • Iron chelation therapy to prevent organ damage from iron overload due to repeated transfusions
  • Antibiotics to treat or prevent infections when white blood cell counts are low
• Growth factors
  • Erythropoiesis-stimulating agents (epoetin alfa, darbepoetin alfa) given as injections to boost red blood cell production
  • Granulocyte colony-stimulating factor (G-CSF) to increase infection-fighting white blood cells
• Chemotherapy
  • Hypomethylating agents (azacitidine, decitabine, or combination decitabine-cedazuridine) to slow disease progression and improve blood counts
  • Typically given in cycles over several months, with ongoing monitoring
• Immunomodulatory therapy
  • Lenalidomide, especially effective for MDS with deletion 5q chromosomal abnormality
  • Taken as a daily pill in cycles to reduce transfusion dependence
• Erythroid maturation agents
  • Luspatercept to help immature red blood cells mature properly
  • Used for specific MDS subtypes with ring sideroblasts
• Immunosuppressive therapy
  • Antithymocyte globulin (ATG) and cyclosporine for selected patients
  • Particularly considered in younger patients with hypoplastic bone marrow
• Stem cell transplantation
  • Allogeneic (donor) stem cell transplant as the only potentially curative option
  • Reserved for younger, healthier patients with higher-risk disease
  • Reduced-intensity transplants may be an option for some older patients
• Experimental therapies in clinical trials
  • Targeted therapies for specific genetic mutations (IDH inhibitors, splicing modulators)
  • Immunotherapy approaches including checkpoint inhibitors
  • Combination treatment regimens testing multiple drugs together

Managing Life with Myelodysplastic Syndrome

Living with MDS involves more than just medical treatments. Patients and their families face physical, emotional, and practical challenges that require attention and support. Taking steps to maintain overall health and well-being can help improve quality of life and may even help the body respond better to treatment.

Preventing Infections

Because MDS often causes low white blood cell counts, preventing infections becomes crucial. Simple habits can significantly reduce infection risk. These include washing hands frequently with soap and water, avoiding crowds during cold and flu season, staying up to date with recommended vaccines (including flu shots and pneumonia vaccines), and avoiding people who are sick. Food safety is also important—thoroughly cooking meat, washing fruits and vegetables, and avoiding unpasteurized dairy products can prevent foodborne illnesses.^[16]

Maintaining Nutrition and Energy

Good nutrition supports the body during MDS treatment. A balanced diet rich in fruits, vegetables, whole grains, and lean proteins provides essential nutrients. However, treatment side effects like nausea, loss of appetite, or changes in taste can make eating difficult. Working with a dietitian can help address these challenges. Eating smaller, more frequent meals throughout the day rather than three large meals may be easier. Some patients find that high-protein snacks help maintain energy levels.^[16]

Staying Active

While fatigue is common in MDS, gentle physical activity can actually help improve energy levels, maintain strength, and enhance mood. Even short walks, light stretching, or simple exercises can be beneficial. The key is to listen to your body and not push too hard. Patients should discuss exercise plans with their healthcare team to ensure activities are appropriate for their current health status and blood counts.^[16]

Emotional and Psychological Support

A diagnosis of MDS can bring feelings of fear, anxiety, anger, or sadness. These emotional responses are normal and valid. Talking with family members, friends, or a mental health professional can help process these feelings. Many patients find support groups, either in-person or online, helpful for connecting with others who understand what they’re going through. Organizations dedicated to blood cancers often provide resources, information, and connections to support networks.^[15]

Some people prefer individual counseling or therapy to work through their emotions. Others find activities like meditation, mindfulness, journaling, or creative pursuits helpful for managing stress and maintaining a sense of normalcy and purpose.^[14]

Practical Considerations

MDS and its treatment can affect work, finances, and daily routines. Patients may need to reduce work hours, take medical leave, or make other adjustments. Understanding employment rights and available financial assistance programs can help ease practical burdens. Social workers or patient navigators at treatment centers can often provide guidance on these issues.^[15]

Regular communication with the healthcare team is essential. Patients should report new symptoms, changes in how they feel, or concerns about treatments. Keeping a list of questions between appointments ensures important topics get addressed during visits. Bringing a family member or friend to appointments can help remember information discussed and provide support.^[17]